Scholarlink

<p>Long-term pharmacological intervention is essential for managing chronic diseases, yet continuous administration of antithrombotic agents often increases bleeding risk, posing a major clinical challenge. Here, we designed a multifunctional drug delivery platform composed of large-aperture mesoporous silica (Mas) coated with silk fibroin (SF) or sustained heparin sodium (HS) release. The well-defined mesoporous structure enables high drug loading, while the biocompatible SF coating regulates release kinetics, suppresses burst release, and prolongs therapeutic efficacy. This dual structural system enhances antithrombotic performance while mitigating hemorrhagic risk. In vitro studies demonstrated improved hemocompatibility and reduced cytotoxicity of SF-Mas/HS compared with free HS. In vivo thrombosis models further confirmed effective inhibition of thrombus formation without excessive bleeding. By integrating inorganic mesoporous carriers with natural protein coatings, SF-Mas/HS provides a safe and efficient strategy for long-term antithrombotic prevention, highlighting the potential of biomaterial-assisted delivery systems to balance efficacy and safety in chronic disease management.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Silk fibroin-coated nanoparticles for safe and efficient antithrombotic drug delivery

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月16日

查看全文
  • Leihao Lu,
  • Qichao Cheng,
  • Jiangfeng Cai,
  • Yumao Zhang,
  • Qing Bao,
  • Yao Miao,
  • Hui Yue,
  • Ying Zhang,
  • Yi Wu,
  • Shuxu Yang,
  • Chuanbin Mao,
  • Mingying Yang

摘要

Long-term pharmacological intervention is essential for managing chronic diseases, yet continuous administration of antithrombotic agents often increases bleeding risk, posing a major clinical challenge. Here, we designed a multifunctional drug delivery platform composed of large-aperture mesoporous silica (Mas) coated with silk fibroin (SF) or sustained heparin sodium (HS) release. The well-defined mesoporous structure enables high drug loading, while the biocompatible SF coating regulates release kinetics, suppresses burst release, and prolongs therapeutic efficacy. This dual structural system enhances antithrombotic performance while mitigating hemorrhagic risk. In vitro studies demonstrated improved hemocompatibility and reduced cytotoxicity of SF-Mas/HS compared with free HS. In vivo thrombosis models further confirmed effective inhibition of thrombus formation without excessive bleeding. By integrating inorganic mesoporous carriers with natural protein coatings, SF-Mas/HS provides a safe and efficient strategy for long-term antithrombotic prevention, highlighting the potential of biomaterial-assisted delivery systems to balance efficacy and safety in chronic disease management.